|
|
||||||||||
|
J Am Coll Cardiol, 2003; 41:2237-2244, doi:10.1016/S0735-1097(03)00491-1 © 2003 by the American College of Cardiology Foundation |








* Institute of Human Genetics, Heidelberg, Germany
Department of Cardiology, University of Heidelberg, Heidelberg, Germany
Department of Pneumology, University of Giessen, Giessen, Germany
Division of Human Genetics, Childrens Hospital Medical Center, Cincinnati, Ohio, USA
|| Department of Pneumology, University of Hannover, Hannover, Germany
¶ Department of Pneumology, University of Leipzig, Leipzig, Germany
* Reprint requests and correspondence: Dr. Bart Janssen, Institute of Human Genetics, Im Neuenheimer Feld 328, 69120 Heidelberg, Germany.
Bart_Janssen{at}med.uni-heidelberg.de
OBJECTIVES: The aim of our study was to identify genetic causes of primary pulmonary hypertension (PPH), to estimate the proportion of families with mutations in the BMPR2 (bone morphogenetic protein receptor type 2) gene, and to examine whether genetic heterogeneity might play a role.
BACKGROUND: The BMPR2 mutations have been identified in a substantial portion of patients with familial or sporadic PPH. However, the genetic cause of PPH remains unclear in at least 45% of families.
METHODS: We investigated 130 members of 10 families with at least 1 PPH patient, recruited without selection for familial disease. Manifest PPH was documented in 21 individuals. An increase in pulmonary artery systolic pressure (PASP) above 40 mm Hg during supine bicycle exercise was found in 46 healthy individuals. Their PASP increased from 21.0 ± 4.6 mm Hg at rest to 54.0 ± 9.8 mm Hg during exercise. In 51 relatives, PASP values were normal at rest and during exercise, and 12 members were classified as status unknown.
RESULTS: Two families showed a mutation in the BMPR2 gene. Three families with no BMBR2 mutation showed evidence for linkage to a more proximal location on chromosome 2q31 (odds ratio [OR] for linkage 1.1·106:1). This locus, designated PPH2, maps in-between the markers D2S335 and D2S2314. We obtained significant support for heterogeneity in PPH with an OR of 2.8·1011.
CONCLUSIONS: We conclude that PPH may be a genetically heterogeneous disorder with at least twoand possibly morecausative genes.
| ||||||||||||||||||||
This article has been cited by other articles:
![]() |
M. Hagen, K. Fagan, W. Steudel, M. Carr, K. Lane, D. M. Rodman, and J. West Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1473 - L1479. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tada, S. Majka, M. Carr, J. Harral, D. Crona, T. Kuriyama, and J. West Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1556 - L1563. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rabinovitch Cellular and Molecular Pathobiology of Pulmonary Hypertension Conference Summary Chest, December 1, 2005; 128(6_suppl): 642S - 646S. [Full Text] [PDF] |
||||
![]() |
M. Rabinovitch Cellular and Molecular Pathobiology of Pulmonary Hypertension Conference Summary Chest, December 1, 2005; 128(6_suppl): 642S - 646S. [Full Text] [PDF] |
||||
![]() |
E. Grunig, C. Dehnert, D. Mereles, R. Koehler, H. Olschewski, P. Bartsch, and B. Janssen Enhanced Hypoxic Pulmonary Vasoconstriction in Families of Adults or Children With Idiopathic Pulmonary Arterial Hypertension Chest, December 1, 2005; 128(6_suppl): 630S - 633S. [Full Text] [PDF] |
||||
![]() |
E. Grunig, C. Dehnert, D. Mereles, R. Koehler, H. Olschewski, P. Bartsch, and B. Janssen Enhanced Hypoxic Pulmonary Vasoconstriction in Families of Adults or Children With Idiopathic Pulmonary Arterial Hypertension Chest, December 1, 2005; 128(6_suppl): 630S - 633S. [Full Text] [PDF] |
||||
![]() |
J. X.-J. Yuan and L. J. Rubin Pathogenesis of Pulmonary Arterial Hypertension: The Need for Multiple Hits Circulation, February 8, 2005; 111(5): 534 - 538. [Full Text] [PDF] |
||||
![]() |
R. E. Harrison, R. Berger, S. G. Haworth, R. Tulloh, C. J. Mache, N. W. Morrell, M. A. Aldred, and R. C. Trembath Transforming Growth Factor-{beta} Receptor Mutations and Pulmonary Arterial Hypertension in Childhood Circulation, February 1, 2005; 111(4): 435 - 441. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Newman, R. C. Trembath, J. A. Morse, E. Grunig, J. E. Loyd, S. Adnot, F. Coccolo, C. Ventura, J. A. Phillips III, J. A. Knowles, et al. Genetic basis of pulmonary arterial hypertension: Current understanding and future directions J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 33S - 39S. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Di Sacco Amfepramone does not cause primary pulmonary hypertension Eur. Respir. J., May 1, 2004; 23(5): 790 - 790. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |